Angus Grant, Ph.D. joined BeiGene in 2020 as Chief Business Executive, bringing more than 25 years of biotechnology experience across multiple key functions, including business development, alliance management, research and development, and regulatory affairs.

Dr. Grant previously served as CEO of the Dementia Discovery Fund, a venture capital fund focused on therapeutics for age-related dementias and neurodegenerative disease. Prior to that, Dr. Grant spent 12 years at Celgene (now a Bristol Myers Squibb company) serving in various executive roles, including Corporate Vice President of Business Development and Vice President of Regulatory Affairs. Earlier in his career, Dr. Grant worked in business development and regulatory roles at Novartis, Merck KGaA, Rhone Poulanc-Rohrer, SmithKline Beecham, and the U.S. Food and Drug Administration’s Center for Biologics.

Dr. Grant currently serves as Chairman of the Board for Toronto Innovation and Acceleration Partners. He received a bachelor’s degree in biology from the University of Richmond, a Ph.D. in anatomy and immunology from the Medical College of Virginia, and completed his postdoctoral training at the National Cancer Institute.